A Phase 4 interventional study of Atorvastatin and Atorvastatin in Acute Coronary Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing atorvastatin in Acute Coronary Syndrome — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Acute Coronary Syndrome.
Among the 17 studies testing atorvastatin in Acute Coronary Syndrome, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 11 in phase 4, and was the 9th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →1 of the 17 studies testing atorvastatin in Acute Coronary Syndrome is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2008.
This study's enrollment of 499 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 300 across the 17 interventional studies. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing atorvastatin in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar to that employed in the ARMYDA-ACS study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Atorvastatin
Drug: Atorvastatin
80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
40mg daily after PCI for 30 days.
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 30 Days Post-percutaneous Coronary Intervention (PCI)
Percentage calculated as: (number of participants who experienced MACE \[death, myocardial infarction, target vessel revascularization\] within 30 days post-PCI) divided by (number of participants who experienced PCI) \* 100. Major Adverse Cardiac Events (MACE) that occurred after 33 days post PCI were excluded.
Time frame: 30 days post PCI
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 8 Hours Post-PCI
Percentage calculated as: (number of participants who experienced MACE within 8 hours post-PCI) divided by (number of participants who experienced PCI) \* 100.
Time frame: 8 hours post PCI
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 24 Hours Post-PCI
Percentage calculated as: (number of participants who experienced MACE within 24 hours post PCI) divided by (number of participants who experienced PCI) \* 100.
Time frame: 24 hours post PCI
Percentage of Participants With Elevated Creatine Kinase-MB (CK-MB)
CK-MB above the upper limit of normal range from baseline (biomarker of myocardial injury); normal range: 0-5.0 nanograms per milliliter (ng/mL).
Time frame: 8 hours, 24 hours and 30 days post PCI
Percentage of Participants With Elevated Troponin I
Troponin I above the upper limit of normal range from baseline (biomarker of myocardial injury): normal range: 0-0.5 nanograms per milliliter (ng/mL).
Time frame: 8 hours, 24 hours and 30 days post PCI
Percentage of Participants With Elevated Myoglobin
Myoglobin above the upper limit of normal from baseline (biomarker of myocardial injury): normal range: 0-109 nanograms per milliliter (ng/mL).
Time frame: 8 hours, 24 hours and 30 days post PCI
Percent Change From Baseline in C-Reactive Protein (CRP)
C-reactive protein percent change from baseline = (post baseline value minus baseline value) divided by baseline value\*100. Includes all CRP samples tested for the study, including samples unaffected and those samples affected by defective high-sensitivity (hs) CRP reagents.
Time frame: Baseline, 8 hours, 24 hours and 30 days
| Milestone | Atorvastatin | Usual Care |
|---|---|---|
| Started | 247 | 252 |
| Treated | 245 | 250 |
| Full analysis set | 163 | 172 |
| Completed | 154 | 164 |
| Not completed | 93 | 88 |
| Withdrew: Not treated | 2 | 2 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Other | 85 | 77 |
| Withdrew: Withdrawal by subject | 2 | 6 |
Percentage calculated as: (number of participants who experienced MACE \[death, myocardial infarction, target vessel revascularization\] within 30 days post-PCI) divided by (number of participants who experienced PCI) \* 100. Major Adverse Cardiac Events (MACE) that occurred after 33 days post PCI were excluded.
| percentage of participants | Atorvastatin | Usual Care |
|---|---|---|
| Total MACE | 14.7 | 15.7 |
| Death | 0.6 | 0.6 |
| Myocardial Infarction | 14.1 | 15.1 |
| Target Vessel Revascularization | 0.0 | 0.0 |
Percentage calculated as: (number of participants who experienced MACE within 8 hours post-PCI) divided by (number of participants who experienced PCI) \* 100.
| percentage of participants | Atorvastatin | Usual Care |
|---|---|---|
| Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 8 Hours Post-PCI | 6.7 | 6.4 |
Percentage calculated as: (number of participants who experienced MACE within 24 hours post PCI) divided by (number of participants who experienced PCI) \* 100.
| percentage of participants | Atorvastatin | Usual Care |
|---|---|---|
| Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 24 Hours Post-PCI | 13.5 | 15.1 |
CK-MB above the upper limit of normal range from baseline (biomarker of myocardial injury); normal range: 0-5.0 nanograms per milliliter (ng/mL).
| percentage of participants | Atorvastatin | Usual Care |
|---|---|---|
| 8 Hours Post-PCI | 11.3 | 13.6 |
| 24 Hours Post-PCI | 15.6 | 18.9 |
| 30 Days Post-PCI | 1.3 | 0.0 |
Troponin I above the upper limit of normal range from baseline (biomarker of myocardial injury): normal range: 0-0.5 nanograms per milliliter (ng/mL).
| percentage of participants | Atorvastatin | Usual Care |
|---|---|---|
| 8 hours post-PCI | 40.4 | 35.5 |
| 24 hours post-PCI | 49.7 | 44.4 |
| 30 days post-PCI | 1.9 | 1.8 |
Myoglobin above the upper limit of normal from baseline (biomarker of myocardial injury): normal range: 0-109 nanograms per milliliter (ng/mL).
| percentage of participants | Atorvastatin | Usual Care |
|---|---|---|
| 8 hours post-PCI | 8.2 | 10.8 |
| 24 hours post-PCI | 3.1 | 4.2 |
| 30 days post-PCI | 1.3 | 0.6 |
C-reactive protein percent change from baseline = (post baseline value minus baseline value) divided by baseline value\*100. Includes all CRP samples tested for the study, including samples unaffected and those samples affected by defective high-sensitivity (hs) CRP reagents.
| percent change in CRP | Atorvastatin | Usual Care |
|---|---|---|
| 8 hours post-PCI | 205.25 ± 67.799 | 234.77 ± 66.135 |
| 24 hours post-PCI | 594.07 ± 110.774 | 543.50 ± 107.730 |
| 30 days post-PCI | 9.01 ± 58.276 | 67.23 ± 56.562 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin | — | 16/245 (6.5%) | 65/245 (26.5%) |
| Usual Care | — | 16/250 (6.4%) | 45/250 (18%) |
| Event | Atorvastatin | Usual Care |
|---|---|---|
| Post procedural myocardial infarctionInjury, poisoning and procedural complications | 4/245 | 7/250 |
| Myocardial infarctionCardiac disorders | 3/245 | 4/250 |
| Acute myocardial infarctionCardiac disorders | 1/245 | 0/250 |
| Atrial fibrillationCardiac disorders | 1/245 | 0/250 |
| PalpitationsCardiac disorders | 1/245 | 0/250 |
| Visual impairmentEye disorders | 1/245 | 0/250 |
| GastritisGastrointestinal disorders | 1/245 | 0/250 |
| Gastritis erosiveGastrointestinal disorders | 1/245 | 0/250 |
| Chest painGeneral disorders | 1/245 | 1/250 |
| DeathGeneral disorders | 1/245 | 0/250 |
| Event | Atorvastatin | Usual Care |
|---|---|---|
| HeadacheNervous system disorders | 29/245 | 18/250 |
| Myocardial infarctionCardiac disorders | 15/245 | 12/250 |
| Back painMusculoskeletal and connective tissue disorders | 14/245 | 7/250 |
| Chest painGeneral disorders | 13/245 | 11/250 |
| Age, Customized(participants) | Atorvastatin | Usual Care | Total |
|---|---|---|---|
| 18 to 44 years | 23 | 9 | 32 |
| 45 to 64 years | 134 | 156 | 290 |
| >= 65 years | 90 | 87 | 177 |
| Sex: Female, Male(Participants) | Atorvastatin | Usual Care | Total |
|---|---|---|---|
| Female | 81 | 77 | 158 |
| Male | 166 | 175 | 341 |
The record gives a start of Sep 2008, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →